Long-term oncological outcomes after multimodal treatment for locally advanced prostate cancer

被引:0
|
作者
Roldan, Fiorella L. [1 ]
Falagario, Ugo Giovanni [2 ,3 ]
Olsson, Mats [2 ]
Salas, Rodolfo Sanchez [2 ]
Aly, Markus [2 ,4 ]
Egevad, Lars [5 ]
Lantz, Anna [2 ,4 ]
Gronberg, Henrik [4 ]
Akre, Olof [2 ]
Hosseini, Abolfazl [2 ,6 ,7 ]
Wiklund, N. Peter [2 ,8 ]
机构
[1] Hosp Clin Barcelona, Serv Urol, Barcelona, Spain
[2] Karolinska Inst, Dept Mol Med & Surg, Sect Urol, Stockholm, Sweden
[3] Univ Foggia, Dept Urol & Organ Transplantat, Viale Luigi Pinto 1, I-71122 Foggia, FG, Italy
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[5] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[6] Danderyd Hosp, Dept Urol, Stockholm, Sweden
[7] Univ Hosp, Dept Urol, Basel, Switzerland
[8] Icahn Sch Med, Dept Urol, Mt Sinai Hlth Syst, New York, NY USA
来源
BJUI COMPASS | 2024年 / 5卷 / 09期
关键词
cancer-specific survival; cystoprostatectomy; locally advanced prostate cancer; radical pelvic surgery; radiotherapy; CYSTOPROSTATECTOMY; RADIOTHERAPY; MORTALITY; THERAPY; VOLUME; TRIAL;
D O I
10.1002/bco2.414
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveThe aim of this study is to evaluate treatment patterns and long-term oncological outcomes of patients with locally advanced prostate cancer (LAPCa).Patients and methodsThis is a population-based study including LAPC (cT3-4, M0) patients from the Stockholm region (Sweden). A sub-analysis was performed in men treated with primary cystoprostatectomy or total pelvic exenteration (TPE) for cT4 prostate cancer (PCa). Cox regression was used to identify predictors of overall mortality (OM) and cancer-specific mortality (CSM). Biochemical progression-free survival (BPFS) and 90 days complications were reported for the radical surgery subgroup.Patients and methodsThis is a population-based study including LAPC (cT3-4, M0) patients from the Stockholm region (Sweden). A sub-analysis was performed in men treated with primary cystoprostatectomy or total pelvic exenteration (TPE) for cT4 prostate cancer (PCa). Cox regression was used to identify predictors of overall mortality (OM) and cancer-specific mortality (CSM). Biochemical progression-free survival (BPFS) and 90 days complications were reported for the radical surgery subgroup.ResultsWe included 2921 patients with cT3(N = 2713) or cT4(N = 208), M0 PCa diagnosed between 2003 and 2019. Out of these, 249(9%), 1497(51%) and 1175(40%) underwent radical prostatectomy, RT + ADT and androgen deprivation therapy (ADT), respectively. Survival rates were 76% (IQR: 68, 83), 47% (IQR: 44, 50) and 23% (IQR: 20, 27), respectively at 10 years. Irrespective of treatment modalities, cT4 patients had worse survival compared to cT3 patients (OM: HR1.44, IQR:1.17,1.77; PCSM: HR1.39, IQR:1.06,1.82). Twenty-seven patients with cT4, N0-1, M0 were treated with cystoprostatectomy or TPE. Twenty-two patients (81.5%) received neoadjuvant ADT. The 5-year BPFS, CSS and OS rates were 39.6%, 68.8% and 63.8%, respectively. Nine patients (33.3%) had Clavien-Dindo grade III and 1 (3.7%) grade IV complication within 90 days after surgery.ConclusionsPelvic surgery with radical intent as part of a multidisciplinary management may be an effective alternative for selected patients with locally advanced PCa leading to local tumour control and an acceptable morbidity.
引用
收藏
页码:885 / 892
页数:8
相关论文
共 50 条
  • [31] Long-term results after laparoscopic distal gastrectomy for locally advanced cancer
    Schroeder, W.
    Bruns, C. J.
    CHIRURGIE, 2022, 93 (10): : 999 - 1000
  • [32] Early Oncological Outcomes for Radical Prostatectomy as Monotherapy in the Management of Locally Advanced Prostate Cancer
    Surcel, C.
    Mirvald, C.
    Gingu, C.
    Iordache, A.
    Manu, M.
    Savu, C.
    Sinescu, I
    UROLOGY, 2012, 80 (03) : S273 - S274
  • [33] WHOLE GLAND SALVAGE CRYOABLATION OF PROSTATE: LONG-TERM ONCOLOGICAL OUTCOMES
    Siddiqui, Khurram
    Billia, Michele
    Violette, Philippe
    Arifin, Andrew
    Tran, KimChi
    Izawa, Jonathan
    Chin, Joseph
    JOURNAL OF UROLOGY, 2016, 195 (04): : E193 - E194
  • [34] Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer
    Milonas, Daimantas
    Venclovas, Zilvinas
    Gudinaviciene, Inga
    Zviniene, Kristina
    Matjosaitis, Aivaras Jonas
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [35] LONG-TERM MORBIDITY AND ONCOLOGICAL OUTCOMES OF SALVAGE CRYOTHERAPY OF RADIO-RECURRENT PROSTATE CANCER
    Billia, Michele
    Siddiqui, Khurram Mutahir
    Mazzola, Clarisse R.
    Goodman, Christopher
    Williams, Andrew
    Chin, Joseph
    JOURNAL OF UROLOGY, 2015, 193 (04): : E1005 - E1005
  • [36] OUTCOMES AFTER SURGICAL TREATMENT OF LOCALLY ADVANCED PROSTATE CANCER: SINGLE CENTRE EXPERIENCE
    Milonas, D.
    Baltrimavicius, R.
    Grybas, A.
    Jievaltas, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 535 - 535
  • [37] Favorable long-term oncological and urinary outcomes of incidental prostate cancer following holmium laser enucleation of the prostate
    Tominaga, Yusuke
    Sadahira, Takuya
    Mitsui, Yosuke
    Maruyama, Yuki
    Tanimoto, Ryuta
    Wada, Koichiro
    Munemasa, Shuhei
    Kusaka, Nobuyuki
    Nishiyama, Yasuhiro
    Kurashige, Takushi
    Nasu, Yasutomo
    Hayata, Shunji
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 10 (06) : 605 - 609
  • [38] Population-based study of long-term functional outcomes after prostate cancer treatment
    Carlsson, Sigrid
    Drevin, Linda
    Loeb, Stacy
    Widmark, Anders
    Lissbrant, Ingela Franck
    Robinson, David
    Johansson, Eva
    Stattin, Par
    Fransson, Per
    BJU INTERNATIONAL, 2016, 117 (6B) : E36 - E45
  • [39] Re: Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2013, 190 (05): : 1764 - 1765
  • [40] Primary chemotherapy in the treatment of locally advanced rectal cancer -: Long-term results
    Pollicino, A
    Gioffrè, MA
    De Renzis, C
    Venuti, A
    XXIII NATIONAL CONGRESS SOCIETA ITALIANA DI CHIRURGIA ONCOLOGICA, 1999, : 619 - 623